Absence of systemic immunologic changes during dose build‐up phase and early maintenance period in effective specific sublingual immunotherapy in children

Summary Background Sublingual immunotherapy (SLIT) has been reported to be a safe treatment for inhalant allergies in children. Yet the immunologic mechanisms resulting in clinical improvement are poorly understood. Objective To identify early systemic immunologic changes during the first 8 weeks of clinically effective SLIT to grass pollen, tree pollen or house dust mite in paediatric patients with allergic rhinoconjunctivitis and/or asthma. Methods Peripheral blood mononuclear cells and plasma samples of 13 children with reduced symptoms after 1 year of SLIT were obtained before therapy and at 2 and 8 weeks after the initiation of SLIT. Allergen‐specific lymphocyte proliferation assays were performed, and allergen‐induced cytokine production (IL‐2, IL‐4, IL‐10, IFN‐γ, and TGF‐β 1 ) was measured by ELISA and flow cytometry. Allergen‐specific IgE, IgG1, IgG4, and IgA levels in plasma samples were determined in ELISA. Results During the first 8 weeks of successful SLIT, allergen‐specific lymphoproliferation ( n =13) as well as levels of allergen‐specific intracellular ( n =8) and secreted cytokines ( n =9) did not change significantly. In addition, no alterations in levels of allergen‐specific Igs ( n =7) were observed. Conclusion We could not find any early systemic immunologic changes during the first 8 weeks of clinically effective SLIT to inhalant allergens in paediatric patients with allergic rhinoconjunctivitis and/or asthma.